ArticleFrontiers in neurology2025
The ROX@PDA@PCL vascularized bionic nerve conduit facilitates the restoration of nerve defects.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous research has highlighted the pivotal role of angiogenesis in facilitating nerve function repair following nerve injury. In this study, we employed polydopamine (PDA) to modify polycaprolactone (PCL) and subsequently loaded it with roxadustat (ROX), thereby constructing a vascularized nerve conduit for the repair of a 10 mm sciatic nerve defect in rats. At 2 weeks post-surgery, new blood vessels were evaluated by immunofluorescence staining. Twelve weeks post-surgery, a comprehensive suite of assessments was conducted to evaluate the efficacy of the conduit, including gait analysis, determination of gastrocnemius muscle wet weight recovery, electrophysiological examination of gastrocnemius compound action potential (CMAP), Masson staining to evaluate gastrocnemius muscle fiber cross-sectional area, toluidine blue staining to assess the total number of regenerated myelinated nerve fibers, and electron microscopic observation of myelin sheath thickness. Our findings revealed that ROX@PDA@PCL could promote the proliferation of vascular endothelial cells and significantly enhance angiogenesis in regenerated nerves (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.